Biotech Values

[marthambles]

the other half is that SNY’s AG launch lessens the upside for Amphastar to launch at-risk in the event that the Judge does not impose a PI.

The problem with this argument is that Amphastar undoubtedly already included in its calculations the strong probability of an authorized generic immediately after it launched.